{
  "id": 3552264,
  "title": "A Mammalian High-Throughput Screen for AI-Designed Peptide-Guided Protein Degraders",
  "url": "https://urgent.news/2026/08/26/a-mammalian-high-throughput-screen-for-ai-designed-peptide-guided",
  "topic": "ai",
  "section": "AI",
  "published": "2026-08-26T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.24.746873v1?rss=1"
  },
  "original_language": "en",
  "account": "A new high-throughput screening method has been developed for identifying peptide-guided ubiquibodies (uAbs) that can degrader targeted proteins within mammalian cells. This platform aims to overcome the limitations of current low-throughput, labor-intensive methods reliant on randomized libraries or non-human display systems.\n\nThe system employs genetically encodable, doxycycline-inducible degraders that fuse peptide guides created by protein language models to the CHIP{Delta}TPR E3 ligase domain. This forms a modular, CRISPR-like setup for precise targeted protein degradation (TPD).\n\nIn the screening process, a pooled uAb library is introduced into fluorescent reporter cell lines specific to each target. Cells with decreased target abundance are isolated using fluorescence-activated cell sorting (FACS), and enriched peptide guides are recovered through sequencing. This approach was tested on several targets, including beta-catenin, GFAP, and EWS::FLI1.\n\nFor beta-catenin, enriched uAbs successfully reduced endogenous beta-catenin abundance and Wnt signaling in DLD1 cells. When GFAP-directed uAbs were used, they decreased endogenous GFAP abundance and cell viability in U251 glioblastoma cells. Additionally, EWS::FLI1-directed uAbs reduced the fusion oncoprotein abundance, suppressed EWSAT1 expression, and increased apoptosis in Ewing sarcoma models.\n\nLastly, a screen using endogenously tagged GATA2 identified uAbs that can lower GATA2 under native genomic regulation. This high-throughput, human cell-based platform successfully connects generative peptide design to functional mammalian selection, providing a scalable strategy for CRISPR-like proteome perturbation.",
  "summary": "Targeted protein degradation (TPD) offers a route to eliminate disease-driving proteins that remain inaccessible to conventional inhibitors. However, degrader discovery remains low-throughput, labor-intensive, and dependent on randomized libraries or non-human display systems, limiting functional selection in mammalian cells. Here, we present a high-throughput, human cell-based platform for…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}